SCHEMBL18352965

SCHEMBL18352965

COc1cc2nc(-c3ccccc3SC)oc(=O)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 11/20 1.00
KLK14 Q9P0G3 11/20 1.00
KLK5 Q9Y337 11/20 1.00
CTSG P08311 9/20 1.00
CTRC Q99895 3/20 1.00
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
HSD17B10 Q99714 3/20 0.57
MAPK1 P28482 1/20 0.57
PRSS1 P07477 1/20 0.57
C1R P00736 1/20 0.56
ELANE P08246 2/20 0.56
ALDH1A1 P00352 2/20 0.55
HPGD P15428 2/20 0.55
MAPT P10636 1/20 0.55
PTK2B Q14289 1/20 0.55
KDM4E B2RXH2 3/20 0.54
LMNA P02545 1/20 0.54
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16946276 0.92 KLK7 (1.00) KLK7KLK14KLK5CTSGCTRC
SCHEMBL30111990 0.92 KLK7 (1.00) KLK7KLK14KLK5CTSGCTRC
SCHEMBL22272031 0.84 MEN1 (1.00) KLK7KLK14KLK5CTSGCTRC
SCHEMBL913416 0.82 KLK7 (1.00) KLK7KLK14KLK5CTSGCTRC
SCHEMBL912875 0.82 KLK7 (0.85) KLK7KLK14KLK5CTSGCTRC
SCHEMBL4202365 0.82 MEN1 (0.75) KLK7KLK14KLK5CTSGCTRC
SCHEMBL914283 0.82 MEN1 (0.75) KLK7KLK14KLK5CTSGCTRC
SCHEMBL30969124 0.80 KLK7 (0.67) KLK7KLK14KLK5CTSGCTRC
SCHEMBL8499615 0.79 KMT2A (0.70) KLK7KLK14KLK5CTSGCTRC
SCHEMBL18353427 0.79 KLK7 (1.00) KLK7KLK14KLK5CTSGCTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3097085-B1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES SIXERA PHARMA AB (SE) 2020-07-29 EP disclosed
US-20170267692-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES SIXERA PHARMA AB (SE) 2017-09-21 US disclosed
US-20170267692-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES SIXERA PHARMA AB (SE) 2017-09-21 US disclosed
US-9695194-B2 Benzoxazinone derivatives for treatment of skin diseases SIXERA PHARMA AB (SE) 2017-07-04 US disclosed
US-9695194-B2 Benzoxazinone derivatives for treatment of skin diseases SIXERA PHARMA AB (SE) 2017-07-04 US disclosed
US-20170002021-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES SIXERA PHARMA AB (SE) 2017-01-05 US disclosed
US-20170002021-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES SIXERA PHARMA AB (SE) 2017-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267692-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES KLK5, KLK14, KLK7 KLK7 3/4885KLK14 2/4885KLK5 1/4885
US-20170002021-A1 BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES KLK5, KLK14, KLK7 KLK7 3/4885KLK14 2/4885KLK5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.